Infections are the main cause of morbidity and mortality in pediatric hematology and oncology (PHO) and hematopoietic cell transplantation (HCT) settings in children and adults. The analysis of incidence and outcome of bacterial, fungal, and viral infections in Polish PHO/ HCT centers was performed over a period of 72 months (2012)(2013)(2014)(2015)(2016)(2017). The summary of infections in 5628 patients with newly diagnosed malignancy and 971 HCTs is presented in this paper. Additionally, data of 650 pediatric HCTs from 2012 to 2015 were compared with the data of 3200 HCTs in adults. The risk of any infection per patient was higher in HCT vs PHO patients (2062/971 vs 7115/5628; 2.1 vs 1.3; HR=1.7, p<0.0001). The incidence of bacterial infections was 34,2±0,6% in PHO vs 41,5±1,6% in HCT patients, and the outcome was better in PHO patients: 97,9±0,2% vs 91,8±1,0%. The incidence of patients with fungal infection was 8,8±0,4% vs 21,2±1,3%, and the outcome was better in PHO patients: 95,9±0,7% vs 85,8±2,3%. Incidence of viral infections was 5,0±1,0% in PHO setting, including part of previously transplanted patients, and 47,8±2,2% in HCT setting (60,9±2,3% allo-HCT; 5,6±1,3% auto-HCT). In children, the incidence was higher for bacterial (36.0% vs 27.6%), fungal (25.3% vs 6.3%), and viral (56.3% vs 29.3% allo-HCT; 6.6% vs 0.8% auto-HCT) infections than in adults (p<0.0001), and the outcome was better for bacterial (95.5% vs 91.4%), fungal (88.0% vs 74.9%), and viral (98.6% vs 92.3%) infections. In conclusion, the presented large studies have determined the incidence of infectious complications and their outcomes in HCT and PHO centers in Poland.
Introduction: nationwide project
Infections are the main cause of morbidity and mortality in patients with cancer or undergoing stem cell transplantation [1] . Children and adults with hematologic malignancies are especially susceptible to bacterial, fungal, and viral infections due to abnormality of the basic mediators of immunity. Factors that predispose these patients to infection include the following: alterations of the body's natural barriers, presence of central venous catheters, alteration of the innate immune system and acquired immunity, as well as intensive oncologic and supportive therapy. 
Definitions

Classification of infections.
Infections during neutropenia were classified as follows: (1) microbiologically documented infection (MDI) when pathogenic microorganism was recovered; (2) clinically documented infection (CDI) with the presence of signs and symptoms of inflammation at anatomic sites and non-recovered pathogen; and (3) fever of unknown origin (FUO) in case of fever without a localized source of infection or identified pathogen [2] . Severe and very severe neutropenia were defined by the peripheral blood absolute neutrophil count (ANC) below 0.5x10 9 /L and 0.2x10 9 /L, respectively.
Infectious episodes.
Following episodes were reported: microbiologically documented bacterial infections; proven/probable/ possible IFI; and latent and sporadic viral infections.
Fungal infections.
The diagnosis of IFD was made according to EORTC/MSG criteria as proven, probable, or possible [3] [4] [5] . All HCT and PHO patients were screened with galactomannan test mainly during neutropenia or on the basis of clinically driven indications.
Viral infections:
They were classified as episodic (diagnosed on the basis of clinical manifestation and supplemented with appropriate tests) or latent (requiring monitoring at the molecular level) [6] [7] [8] . Following latent viruses were included in the analysis: cytomegalovirus (CMV); Epstein-Barr virus (EBV); varicella-zoster virus (VZV); human herpes virus 6 (HHV6); polyoma BK virus (BKV); and episodic viruses as follows: influenza (FLU), CARV (community-acquired respiratory virus, parainfluenza (PIF), metapneumovirus (MPV), respiratory syncytial virus (RSV)), and adenovirus (ADV). According to European Conference on Infections in Leukemia (ECIL) recommendations, preemptive approach was introduced for infections with two latent viruses: CMV and EBV [7, 8] . PCR-based analysis was used for diagnosis of viral infections of material derived from blood, urine, or cerebrospinal fluid. CARV viruses were detected by PCR from respiratory swabs or bronchoalveolar lavage. 
Prophylaxis of infections
Overall incidence of infections in pediatric HCT vs PHO settings
A total number of 9177 confirmed infectious episodes were reported.
The incidence was higher in HCT patients (n=971) than in PHO patients (n=5628) for bacterial (41.5% vs 34.2%, HR=1.4, 95% CI=1.2-1.6, p<0.0001), proven/probable/possible fungal (21.2% vs 8.8%, HR=2.8, 95% CI=2.3-3.3, p<0.0001), proven/probable IFI (9.5% vs 3.0%, HR=3.3, 95% CI=2.5-4.3, p<0.0001), and viral (47.8% vs 5.0%, HR=22, 95% CI=18.5-26.4, p<0.0001) infections [15] . The incidence of viral infections varied largely between allo-HCT (60.9%; 451/741) and auto-HCT (5.6%; 13/230). The risk of any infection per patient was higher in HCT vs PHO patients (2062/971 vs 7115/5628; 2.1 vs 1.3; HR=1.7, 95% CI=1.5-1.8, p<0.0001) ( Fig. 1.) .
Overall results on incidence and outcome of infections during the first analyzed period were published previously [16] .
Infections in pediatric hematology and oncology setting
Acute lymphoblastic leukemia (ALL)
The analysis included 1363 patients, with newly diagnosed ALL 
Acute myeloid leukemia (AML)
In the study of the epidemiology and profile of bacterial infections (BI), invasive fungal disease (IFD) and viral infections (VI) in 250 children with initial AML (iAML) and 61 with relapsed/refractory (rAML) [18] . 
Fig. 1. Overall cumulative incidence of infections in pediatric hematology and oncology (PHO) and pediatric hematopoietic stem cell transplantation (HCT) settings between 2012 and 2017: (A and B) including possible, probable, and proven IFD; (C and D) including probable and proven but not possible IFD
A C B D Fig. 1 
. Overall cumulative incidence of infections in pediatric hematology and oncology (PHO) and pediatric hematopoietic stem cell transplantation (HCT) settings between 2012 and 2017: (A and B) including possible, probable, and proven IFD; (C and D) including probable and proven but not possible IFD
Bone tumors
Infectious complications in 70 children with Ewing sarcoma (ES) and 56 with osteosarcoma (OSA) showed that the risk of infection [20] .
Clostridium difficile infections
Clostridium difficile infection is one of the most common causes of nosocomial infectious diarrhea in children in PHO and HCT settings.
Episodes of CDI occurred in 14% PHO patients. The incidence of CDI was higher in patients with hematological malignancies in comparison to that with solid tumors. Patients with acute myeloblastic leukemia had shorter time to episode of CDI than those with acute lymphoblastic leukemia. Patients over 5 years and treated for acute leukemia had more severe clinical course of disease in PHO group. In HSCT group, CDI occurred in 8% patients. The incidence of CDI was higher in patients transplanted for acute leukemia. The recurrence rate was 14.7% in PHO and 20.7% in HSCT patients. CDI incidence was highest in patients with hematological malignancies. Most of the patients experienced mild CDI [21] .
Fungal infections in PHO patients
Incidence. IFD incidence among all pediatric patients treated for malignancy was 9.2%, including possible in 6.5%, probable in 1.6%, and proven IFD in 1.1%. Introduction of antifungal prophylaxis from 2014 to 2015 in selected groups of patients (AML and high-risk ALL) did not change significantly the incidence of IFD in this setting: from 10.2% in first period to 8.3% in the third one (ns). In AML patients, the incidence of proven/probable IFD decreased from 19.7% in the first period to 10.8% in the second and to 8.4% in last one, while possible IFD from 23.5% and 25.7% to 14.8% in respective periods of time. In ALL patients, proven/probable IFD ranged from 6.7% to 4.9% and 4.8% in respective periods; however, incidence of possible IFD increased from 6.3% to 9.8% and 19.1% in respective periods [15, 22] .
Outcome. Success rate of treatment of IFD was 95.9% in pediatric malignancy patients. With respect to the level of diagnosis of IFD, the outcome was 94.3% for proven, 92.4% for probable, and 96.9% for possible IFD. The outcome was 96.2% for children with ALL and 93.4% with AML [15] . patients with primary immunodeficiencies [23, 24] .
Bacterial infections in HCT pediatric patients
Fungal infections in HCT pediatric patients
Incidence. IFD incidence among pediatric HCT patients was 20.6%, including possible in 12.0%, probable in 5.3%, and proven IFD in 3.3%. Introduction of antifungal prophylaxis from 2014 to 2015 (in patients in early phase after HCT or with GVHD) resulted in significant decrease in incidence of IFD in HCT patients from 27.0% in 2012-2013 to 11.7% in 2016-2017 (p<0.001). In AML patients, the frequency of proven/probable IFD decreased from 19.2% in first period to 17.6% in second period and to 1.5% in the third one while possible IFD from 25.5% to 21.6% and 17.4% in respective periods.
In ALL patients, the incidence of proven/probable IFD decreased from 17.9% to 12.7% and 1.4% in respective periods while possible IFD varied from 13.4% and 15.2% to 11.3% in respective periods [15, 22] .
Outcome. Overall outcome of IFD was 85.8%. With respect to the level of diagnosis of IFD, the outcome was 90.2%, for proven, 76.9% for probable, and 88.7% for possible IFD. The outcome was 84.7% for children with ALL and 84.8% with AML [15] .
Viral infections in HCT pediatric patients
Incidence. The cumulative incidence was 57.9% in allo-HCT and 4.8% in auto-HCT patients. More than one pathogen was diagnosed in 46.0% of allo-HCT patients. Cumulative incidence of viral infections was 28.9% for CMV, 23.8% for BKV, 22.7% for EBV, 10.7% for ADV, 5.0% for RV, 1.9% for FLU, 1.2% for VZV, 1.2% for HHV-6, 0.7% for RSV, 0.5% NV, 0.4% for PIF, 0.4% for RHINO, 0.3% for HSV, 0.1% for hMPV, 0.1% for PVB19, and 0.1% for HBV.
Survival. Success rates were 100% after FLU, HBV, VZV, HHV6, or RV infections, and lower in other types of infections: EBV (90.7%), ADV (93.8%), BKV (94.2%), and CMV (94.6%) [15, 25, 26] .
Children versus adults: infections are more frequent and have better outcome in children
Incidence. Pediatric patients had 2.9-fold higher incidence of infectious complications than adults. Infections were diagnosed in 60.8% children and 35.0% adults, including 69.1% vs 63.5% in allo-HCT, and 33.1% vs 20.8% in auto-HCT patients, respectively.
Bacterial infections were more frequent in children (36.0% vs 27.6%).
In adults, G-negative bacteria were more frequent than G-positive (64.6% vs 44.8%). The incidence was higher in children also for IFD (25.3% vs 6.3%), and viral infections both after allo-HCT (56.3% vs 29.3%) and auto-HCT (6.6% vs 0.8%).
Outcome. Pediatric patients had 2.5-fold better survival of infections than adults. Children had better survival from bacterial (95.5% vs 91.4%; p=0.0011), fungal (88.0% vs 74.9%; p<0.001), and viral (98.6% vs 92.3%; p=0.0096) infections. Infection-related mortality was lower in children (7.8% vs 18.4%; p<0.0001). No child died of infection after auto-HCT. In multivariate analysis, the risk factors for death from infection were following: adult vs children, diagnosis of acute leukemia, mismatched transplants, chronic GVHD, infection with Gram-negative bacteria, CMV reactivation, and also duration of infection >21 days [27] .
Conclusions
Presented large studies have determined the incidence of infectious complications and their outcome in pediatric HCT and PHO departments, as well as adult HCT centers in Poland. Emerging data from Polish PHO and HCT centers indicate high incidence of infectious complications in these populations [28] [29] [30] . Although the rate of bacterial infections is similar to data reported from international centers both for children and adults, our data suggest that the incidence of IFD in pediatric ALL and AML both in PHO and HCT settings is much higher than it was recently anticipated. Viral infections occur in a high rate of allo-HCT pediatric and adult patients, thus might severely compromise the overall benefit of transplant.
